AAA
AXSM icon

Affinity Asset Advisors’s Axsome Therapeutics AXSM Stock Holding History

Affinity Asset Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,000
Closed -$2.04M – 73
2020
Q4 		$2.04M Buy
+25,000
New +$1.87M 1.08% 28

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Affinity Asset Advisors's AXSM Position: Q3 2025 in Review

Affinity Asset Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 50,000 shares — an estimated $5.22M sold.

Affinity Asset Advisors first reported a position in AXSM in Q4 2020 and held it in 11 quarters. The position peaked at $11.7M in Q1 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Affinity Asset Advisors reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 50,000 Axsome Therapeutics shares in Q3 2025, an estimated $5.22M.
  • Affinity Asset Advisors first reported a position in Axsome Therapeutics in Q4 2020 and held it in 11 quarters.
  • Affinity Asset Advisors's Axsome Therapeutics position peaked at $11.7M in Q1 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.